$PIRS
Pieris Pharmaceuticals Inc Stock $pirs

$pirs Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000158364822000025 Filed on May 11, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$10.99M	$15.63M
YoY Change	-29.71%	17.89%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.379M	$4.130M
YoY Change	6.03%	-5.28%
% of Gross Profit
Research & Development	$14.07M	$16.56M
YoY Change	-15.07%	29.82%
% of Gross Profit
Depreciation & Amortization	$845.0K	$630.0K
YoY Change	34.13%	85.84%
% of Gross Profit
Operating Expenses	$18.45M	$20.69M
YoY Change	-10.86%	20.89%
Operating Profit	-$7.457M	-$5.059M
YoY Change	47.4%	31.2%
Interest Expense	-$3.000K	$3.000K
YoY Change	-200.0%	-99.06%
% of Operating Profit
Other Income/Expense, Net	$229.0K	$884.0K
YoY Change	-74.1%	-1573.33%
Pretax Income	-$5.101M	-$4.170M
YoY Change	22.33%	15.83%
Income Tax
% Of Pretax Income
Net Earnings	-$5.100M	-$4.200M
YoY Change	21.43%	16.67%
Net Earnings / Revenue	-46.41%	-26.87%
Basic Earnings Per Share	-$0.07	-$0.07
Diluted Earnings Per Share	-$0.07	-$0.07
COMMON SHARES
Basic Shares Outstanding	73.71M shares	56.30M shares
Diluted Shares Outstanding	73.71M shares	56.30M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$100.3M	$66.80M
YoY Change	50.1%	-23.04%
Cash & Equivalents	$83.74M	$66.84M
Short-Term Investments	$16.53M
Other Short-Term Assets	$9.837M	$5.600M
YoY Change	75.66%	30.23%
Inventory
Prepaid Expenses
Receivables	$1.644M	$15.81M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$111.7M	$88.27M
YoY Change	26.6%	-10.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$18.85M	$20.51M
YoY Change	-8.11%	0.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.673M	$3.213M
YoY Change	-16.81%	70.27%
Total Long-Term Assets	$25.37M	$27.51M
YoY Change	-7.81%	8.32%
TOTAL ASSETS
Total Short-Term Assets	$111.7M	$88.27M
Total Long-Term Assets	$25.37M	$27.51M
Total Assets	$137.1M	$115.8M
YoY Change	18.42%	-6.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.496M	$3.467M
YoY Change	29.68%	-0.94%
Accrued Expenses	$11.86M	$9.562M
YoY Change	24.01%	37.8%
Deferred Revenue	$20.91M	$17.24M
YoY Change	21.33%	71.6%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$39.48M	$30.27M
YoY Change	30.46%	47.76%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$44.18M	$0.00
YoY Change		-100.0%
Total Long-Term Liabilities	$44.18M	$0.00
YoY Change		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.48M	$30.27M
Total Long-Term Liabilities	$44.18M	$0.00
Total Liabilities	$83.67M	$77.55M
YoY Change	7.89%	4.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$262.2M	-$215.6M
YoY Change	21.61%	21.28%
Common Stock	$314.7M	$253.6M
YoY Change	24.1%	10.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$53.45M	$38.24M
YoY Change
Total Liabilities & Shareholders Equity	$137.1M	$115.8M
YoY Change	18.42%	-6.45%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$5.100M	-$4.200M
YoY Change	21.43%	16.67%
Depreciation, Depletion And Amortization	$845.0K	$630.0K
YoY Change	34.13%	85.84%
Cash From Operating Activities	-$22.64M	-$12.14M
YoY Change	86.55%	-19.78%
INVESTING ACTIVITIES
Capital Expenditures	$389.0K	$28.00K
YoY Change	1289.29%	-98.55%
Acquisitions
YoY Change
Other Investing Activities	-$16.56M	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$16.95M	-$28.00K
YoY Change	60428.57%	-106.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$6.473M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$6.558M	$9.693M
YoY Change	-32.34%
NET CHANGE
Cash From Operating Activities	-$22.64M	-$12.14M
Cash From Investing Activities	-$16.95M	-$28.00K
Cash From Financing Activities	$6.558M	$9.693M
Net Change In Cash	-$34.03M	-$3.601M
YoY Change	844.93%	-75.72%
FREE CASH FLOW
Cash From Operating Activities	-$22.64M	-$12.14M
Capital Expenditures	$389.0K	$28.00K
Free Cash Flow	-$23.03M	-$12.17M
YoY Change	89.31%	-28.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001583648
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2022Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-37471
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	PIERIS PHARMACEUTICALS, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-0784346
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	255 State Street,
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	9th Floor
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston,
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022Q1	dei	Entity Address Country EntityAddressCountry	US
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02109
CY2022Q1	dei	City Area Code CityAreaCode	857
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	246-8998
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2022Q1	dei	Trading Symbol TradingSymbol	PIRS
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74101330	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83737000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	117764000	USD
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	16531000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1644000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3313000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9837000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6548000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	111749000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	127625000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18849000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19122000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3844000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3909000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2673000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2904000	USD
CY2022Q1	us-gaap	Assets Assets	137115000	USD
CY2021Q4	us-gaap	Assets Assets	153560000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4496000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8609000	USD
CY2022Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	14075000	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	16836000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	20913000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25116000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	39484000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	50561000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	30819000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	38403000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13362000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13841000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	83665000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	102805000	USD
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	74000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	72000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	314668000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	306998000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	953000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	829000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-262245000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-257144000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	53450000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	50755000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137115000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	153560000	USD
CY2022Q1	pirs	Revenue Not From Contract With Customer Grant Income RevenueNotFromContractWithCustomerGrantIncome	2130000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11180000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	14866000	USD
CY2022Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	-192000	USD
CY2021Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	767000	USD
CY2022Q1	us-gaap	Revenues Revenues	10988000	USD
CY2021Q1	us-gaap	Revenues Revenues	15633000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14066000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16562000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4379000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4130000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	18445000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	20692000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7457000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5059000	USD
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-3000	USD
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3000	USD
CY2021Q1	pirs	Revenue Not From Contract With Customer Grant Income RevenueNotFromContractWithCustomerGrantIncome	0	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	229000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	884000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5101000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4172000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	143000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	489000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-19000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4977000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3683000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73711000	shares
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73711000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56297000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56297000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	31027000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4172000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	489000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1199000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	20000	USD
CY2021Q1	pirs	Stock Issued During Period Value Conversion Of Preferred Stock StockIssuedDuringPeriodValueConversionOfPreferredStock	9673000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	38236000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	50755000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5101000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	143000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-19000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1178000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	85000	USD
CY2021Q1	pirs	Operating Lease Right Of Use Asset Accretion OperatingLeaseRightOfUseAssetAccretion	25000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	53450000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5101000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4172000	USD
CY2022Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	845000	USD
CY2021Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	625000	USD
CY2022Q1	pirs	Operating Lease Right Of Use Asset Accretion OperatingLeaseRightOfUseAssetAccretion	5000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1178000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1199000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-91000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	41000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	19651000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	9724000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22643000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12138000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	389000	USD
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	16559000	USD
CY2021Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16948000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	85000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	20000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9673000	USD
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	300000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6473000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6558000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9693000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-994000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1128000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34027000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3601000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117764000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66835000	USD
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-19000	USD
CY2021Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70436000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83737000	USD
CY2022Q1	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	298000	USD
CY2021Q1	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	36000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	100300000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5100000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4200000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-262200000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; determination of the incremental borrowing rate to calculate right-of-use assets and lease liabilities; beneficial conversion features; fair value of stock options, preferred stock, and warrants; and prepaid and accrued clinical trial expenses. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	The Company has no financial instruments with off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does not obtain collateral.
CY2022Q1	us-gaap	Revenues Revenues	10988000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1829000	USD
CY2021Q1	us-gaap	Revenues Revenues	15633000	USD
CY2017Q2	pirs	Number Of Technology Licenses NumberOfTechnologyLicenses	5	lease_agreement
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	10600000	USD
CY2021Q2	us-gaap	Grants Receivable GrantsReceivable	14200000	EUR
CY2021Q2	us-gaap	Grants Receivable GrantsReceivable	17000000	USD
CY2022Q1	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	62653000	USD
CY2021Q4	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	56885000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18849000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	16550000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	21000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	16531000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	27026000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26839000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8177000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7717000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2980000	USD
CY2022Q1	pirs	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	1580000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19122000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1156000	USD
CY2021Q4	pirs	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	1610000	USD
CY2022Q1	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	5745000	USD
CY2021Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	5682000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2454000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3581000	USD
CY2022Q1	pirs	Accrued License Obligations Current AccruedLicenseObligationsCurrent	1500000	USD
CY2021Q4	pirs	Accrued License Obligations Current AccruedLicenseObligationsCurrent	1541000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1003000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1049000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	637000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	393000	USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	14075000	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	16836000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	39400000	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	38600000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74097918	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74097918	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72222661	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72222661	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15617	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15617	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15617	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15617	shares
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	349000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	377000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	159000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	182000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	508000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	559000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y2M12D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	600000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	700000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2193000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2193000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2193000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2193000	USD
CY2022Q1	pirs	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	12247000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	22848000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8483000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	14365000	USD

Files In Submission

Name	View Source	Status
0001583648-22-000025-index-headers.html	Edgar Link	pending
0001583648-22-000025-index.html	Edgar Link	pending
0001583648-22-000025.txt	Edgar Link	pending
0001583648-22-000025-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pirs-20220331.htm	Edgar Link	pending
pirs-20220331.xsd	Edgar Link	pending
pirs-20220331_cal.xml	Edgar Link	unprocessable
pirs-20220331_def.xml	Edgar Link	unprocessable
pirs-20220331_htm.xml	Edgar Link	completed
pirs-20220331_lab.xml	Edgar Link	unprocessable
pirs-20220331_pre.xml	Edgar Link	unprocessable
pirs033122_exx101.htm	Edgar Link	pending
pirs033122_exx101001.jpg	Edgar Link	pending
pirs033122_exx101002.jpg	Edgar Link	pending
pirs033122_exx101003.jpg	Edgar Link	pending
pirs033122_exx101004.jpg	Edgar Link	pending
pirs033122_exx101005.jpg	Edgar Link	pending
pirs033122_exx101006.jpg	Edgar Link	pending
pirs033122_exx101007.jpg	Edgar Link	pending
pirs033122_exx101008.jpg	Edgar Link	pending
pirs033122_exx101009.jpg	Edgar Link	pending
pirs033122_exx101010.jpg	Edgar Link	pending
pirs033122_exx101011.jpg	Edgar Link	pending
pirs033122_exx101012.jpg	Edgar Link	pending
pirs033122_exx101013.jpg	Edgar Link	pending
pirs033122_exx101014.jpg	Edgar Link	pending
pirs033122_exx101015.jpg	Edgar Link	pending
pirs033122_exx101016.jpg	Edgar Link	pending
pirs033122_exx101017.jpg	Edgar Link	pending
pirs033122_exx101018.jpg	Edgar Link	pending
pirs033122_exx101019.jpg	Edgar Link	pending
pirs033122_exx101020.jpg	Edgar Link	pending
pirs033122_exx101021.jpg	Edgar Link	pending
pirs033122_exx101022.jpg	Edgar Link	pending
pirs033122_exx101023.jpg	Edgar Link	pending
pirs033122_exx101024.jpg	Edgar Link	pending
pirs033122_exx101025.jpg	Edgar Link	pending
pirs3-31x22ex311.htm	Edgar Link	pending
pirs3-31x22ex312.htm	Edgar Link	pending
pirs3-31x22ex321.htm	Edgar Link	pending
pirs3-31x22ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIRS
Pieris Pharmaceuticals Inc Stock $pirs

2022 Q1 Form 10-Q Financial Statement

#000158364822000025 Filed on May 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS Pieris Pharmaceuticals Inc Stock $pirs

2022 Q1 Form 10-Q Financial Statement

#000158364822000025 Filed on May 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS
Pieris Pharmaceuticals Inc Stock $pirs